Histogen Announces Initial Close of Series A Financing Round

Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the initial close of Series A financing at $5.35 million.

San Diego, CA (PRWEB) May 2, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced the initial close of Series A financing at $5.35 million. The round was completed by private and corporate investors, including Secure Medical Inc., CellCeuticals Skin Care Inc., and Leonard H. Lavin, founder and Chairman Emeritus of the Alberto-Culver Company.

Histogen will utilize the round to fund Phase 1 clinical trials for hair growth and complete 510k submissions for wound and hernia repair applications. The round will also enable the company to upscale manufacturing for ExceltrixTM, Histogen's human Extracellular Matrix product, and HGEN-001, Histogen's proprietary liquid formulation.

"We are pleased that we have exceeded our original target for the Series A round, and have added highly experienced investors to our list of shareholders," said Gail K. Naughton, Ph.D., CEO of Histogen. "With the close of this financing, we look forward to bringing additional talent to our already seasoned team, and getting our first products to market within the next 12 months."

The initial close of Series A financing will allow Histogen to maintain timelines for product introductions, including the company's first tissue engineering products, which are slated for launch in late 2008 and early 2009. From two product families, Exceltrix and HGEN-001, which are derived from a single manufacturing process, Histogen forsees a breadth of applications in a variety of markets, from research tools to cosmeceuticals.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families -- ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and HGEN-001, Histogen's proprietary liquid formula. For more information, please visit http://www.histogeninc.com.

# # #

Simillar Articles

		Alberto-Culver Founder Leonard Lavin Joins Histogen Board of Directors
		Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today announced that Leonard Lavin, founder and chairman emeritus of the...
		Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
		Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, today launched BioNuesisTM, the only soluble human extracellular matrix (ECM)...
		Histogen Presents Feasability Data on Hair Growth and Laser Resurfacing
		Evaluations of HGEN-001 formulation indicate capabilities for new hair follicle creation and more rapid healing post-laser resurfacing.
		BioCardia Completes $7.4 Million Private Equity Financing Following Successful Phase I Clinical...
		BioCardia, Inc., a regenerative medicine company, today announced the completion of a new round of financing, raising $7.4 million from existing and new investors.
		Continuing Biotech Growth in Switzerland, Says Swiss Biotech Industry Report for 2007
		The report, announced by partner organization Greater Zurich Area AG, presents Switzerland as a thriving location for Biotech and Life Sciences with excellent conditions for business, investments,...